Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYR-PB21 after unilateral total knee arthroplasty
ChiCTR2400082366Phase 2Not yet recruiting
- Sponsor
- Beijing Jishuitan Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HYR-PB21 in postoperative pain (4 arms), sponsored by Beijing Jishuitan Hospital. Primary endpoint: AUC NRS-R, 0-72h. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
HYR-PB21
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2400082366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082366.